Literature DB >> 19598009

Gene delivery efficiency in bone marrow-derived dendritic cells: comparison of four methods and optimization for lentivirus transduction.

Gong-Bo Li1, Guang-Xiu Lu.   

Abstract

Many gene delivery methods have been used to transduce or transfect bone marrow-derived dendritic cells (BMDCs) for genetic engineered DC vaccine research. The present study, for the first time, evaluated the efficiencies of four methods (lipofection, DNA electroporation, recombinant adeno-associated virus type 2 (rAAV2) transduction, and recombinant lentivirus (rLV) transduction) using EGFP as a report gene in the same BMDC culture system. Our data demonstrate that rLV transduction is the most effective method; both lipofection and DNA electroporation transfect BMDCs at lower efficiencies; rAAV2 can hardly transduce BMDCs. Furthermore, our results, for the first time, demonstrate that rLV transduction efficiency on BMDCs can be improved significantly by co-centrifugation and repeated transduction.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19598009     DOI： 10.1007/s12033-009-9197-1

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN： 1073-6085            Impact factor:   2.695


  12 in total

1.  CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells.

Authors:  Y Zhang; N Chirmule; G p Gao; J Wilson
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints.

Authors:  Redouane Rouas; Rathviro Uch; Yvette Cleuter; François Jordier; Claude Bagnis; Patrice Mannoni; Philippe Lewalle; Philippe Martiat; Anne Van den Broeke
Journal:  Cancer Gene Ther       Date:  2002-09       Impact factor: 5.987

3.  Efficient genetic modification of murine dendritic cells by electroporation with mRNA.

Authors:  Sonja Van Meirvenne; Lieven Straetman; Carlo Heirman; Melissa Dullaers; Catherine De Greef; Viggo Van Tendeloo; Kris Thielemans
Journal:  Cancer Gene Ther       Date:  2002-09       Impact factor: 5.987

4.  An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow.

Authors:  M B Lutz; N Kukutsch; A L Ogilvie; S Rössner; F Koch; N Romani; G Schuler
Journal:  J Immunol Methods       Date:  1999-02-01       Impact factor: 2.303

5.  Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.

Authors:  S Yang; C E Vervaert; J Burch; J Grichnik; H F Seigler; T L Darrow
Journal:  Int J Cancer       Date:  1999-11-12       Impact factor: 7.396

6.  Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity.

Authors:  Yukai He; Jiying Zhang; Zhibao Mi; Paul Robbins; Louis D Falo
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

7.  Lentivirally transduced dendritic cells as a tool for cancer immunotherapy.

Authors:  Karine Breckpot; Melissa Dullaers; Aude Bonehill; Sonja van Meirvenne; Carlo Heirman; Catherine de Greef; Pierre van der Bruggen; Kris Thielemans
Journal:  J Gene Med       Date:  2003-08       Impact factor: 4.565

8.  In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.

Authors:  L Naldini; U Blömer; P Gallay; D Ory; R Mulligan; F H Gage; I M Verma; D Trono
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

9.  More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC.

Authors:  Chun-min Liang; Sheng-long Ye; Cui-ping Zhong; Ning Zheng; Wei Bian; Rui-xia Sun; Jun Chen; Ri-lun Li; Shuang Zhou; Yin-kun Liu
Journal:  Mol Immunol       Date:  2007-05-22       Impact factor: 4.407

10.  Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column.

Authors:  A Auricchio; M Hildinger; E O'Connor; G P Gao; J M Wilson
Journal:  Hum Gene Ther       Date:  2001-01-01       Impact factor: 5.695
View more
  6 in total

1.  Comparison of Lentiviral Packaging Mixes and Producer Cell Lines for RNAi Applications.

Authors:  Christian Albrecht; Stefanie Hosiner; Brigitte Tichy; Silke Aldrian; Stefan Hajdu; Sylvia Nürnberger
Journal:  Mol Biotechnol       Date:  2015-06       Impact factor: 2.695

2.  A new chemical complex can rapidly concentrate lentivirus and significantly enhance gene transduction.

Authors:  Jing-Yu Lee; Hu-Hui Lee
Journal:  Cytotechnology       Date:  2017-09-07       Impact factor: 2.058

3.  Genetically modified adipose tissue-derived stem/stromal cells, using simian immunodeficiency virus-based lentiviral vectors, in the treatment of hemophilia B.

Authors:  Natsumi Watanabe; Kazuo Ohashi; Kohei Tatsumi; Rie Utoh; In Kyong Shim; Kazuko Kanegae; Yuji Kashiwakura; Tsukasa Ohmori; Yoichi Sakata; Makoto Inoue; Mamoru Hasegawa; Teruo Okano
Journal:  Hum Gene Ther       Date:  2013-03       Impact factor: 5.695

Review 4.  Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.

Authors:  Yu-Zhe Chen; Xing-Lei Yao; Yasuhiko Tabata; Shinsaku Nakagawa; Jian-Qing Gao
Journal:  Clin Dev Immunol       Date:  2010-12-20

5.  Toward Biological Pacing by Cellular Delivery of Hcn2/SkM1.

Authors:  Anna M D Végh; Arie O Verkerk; Lucía Cócera Ortega; Jianan Wang; Dirk Geerts; Mischa Klerk; Kirsten Lodder; Ruby Nobel; Anke J Tijsen; Harsha D Devalla; Vincent M Christoffels; Max Medina-Ramírez; Anke M Smits; Hanno L Tan; Ronald Wilders; Marie José T H Goumans; Gerard J J Boink
Journal:  Front Physiol       Date:  2021-01-06       Impact factor: 4.566

6.  Harnessing dendritic cells for tumor antigen presentation.

Authors:  Stefan Nierkens; Edith M Janssen
Journal:  Cancers (Basel)       Date:  2011-04-26       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.